Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of iQ-007

PHASE1RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

April 8, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Drug Resistant EpilepsyFocal Seizure
Interventions
DRUG

iQ-007

Highly selective, orally bioavailable, positive allosteric modulator (PAM) of the excitatory amino acid transporter-2 (EAAT2) and its rodent homologue (glutamate transporter-1\[GLT-1).

DRUG

Placebo

Oral capsules identical in appearance to drug and containing vehicle only (Gelucire/Capmul-M).

Trial Locations (1)

5000

RECRUITING

CMAX Clinical Research Pty Ltd, Adelaide

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Avance Clinical Pty Ltd.

INDUSTRY

lead

iQure Australia Pty Ltd

INDUSTRY